BO 653

Drug Profile

BO 653

Latest Information Update: 01 Mar 2005

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chugai Pharmaceutical
  • Class Antihyperlipidaemics
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Coronary artery restenosis

Most Recent Events

  • 10 Feb 2005 Discontinued - Phase-I for Atherosclerosis in Japan (PO)
  • 10 Feb 2005 Discontinued - Phase-I for Coronary artery restenosis in Japan (PO)
  • 10 Feb 2005 Discontinued - Phase-II for Atherosclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top